+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults



P-glycoprotein (Pgp) modulation in untreated acute myeloid leukemia (AML): Cancer and Leukemia Group B (CALGB) trials in younger and older adults



Annals of Hematology 83 Suppl 1: S103-S104




(PDF emailed within 0-6 h: $19.90)

Accession: 049839849

Download citation: RISBibTeXText

PMID: 15124695

DOI: 10.1007/s00277-004-0850-2


Related references

P-glycoprotein modulation in untreated acute myeloid leukemia Cancer and leukemia group B trials in younger and older adults. Annals of Hematology 83(Supplement 1): S103-S104, 2004

Cancer and leukemia group B (CALGB) multidrug resistance modulation trials in untreated acute myeloid leukemia. 2006

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Journal of Clinical Oncology 22(21): 4290-4301, 2004

Intensive post-remission therapy with Ara-C in adults with acute myeloid leukemia: initial results of a CALGB phase III trial. The Cancer and Leukemia Group B. Leukemia 6 Suppl 2: 66-67, 1992

Wilms tumor 1 (WT1) gene mutations predict poor outcome in adults with cytogenetically normal (CN) acute myeloid leukemia (AML): A cancer and leukemia group B (CALGB) study. 2007

Parallel phase I trials of multi-drug resistance modulation with PSC-833 in untreated patients with acute myeloid leukemia 60 years old Preliminary results of CALGB 9621. Blood 94(10 SUPPL 1 PART 1): 384a, Nov 15, 1999

Dose escalation studies of ara-C , daunorubicin and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia 60 years Final induction results of CALGB 9621. Blood 98(11 Part 1): 461a, November 16, 2001

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116(9): 1413-1421, 2010

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111(11): 5371-5379, 2008

Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study. Journal of Clinical Oncology 23(3): 482-493, 2004

Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study. Yearbook of Oncology 2006: 174-175, 2006

Cancer and leukemia group b calgb studies in acute myeloid leukemia. Gale, R P (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 134 Acute Myelogenous Leukemia: Progress And Controversies; Wyeth-Ayerst-Ucla Western Workshop, Lake Lanier, Georgia, Usa, November 28-December 1, 1989 Xxvi+500p Wiley-Liss: New York, New York, Usa; Chichester, England, Uk Illus 313-322, 1990

Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. Annals of Hematology 83 Suppl 1: S84-S85, 2004

ATP-binding cassette (ABC) proteins in untreated acute myeloid leukemia (AML) in patients 60 years and older (CALGB 9760). Journal of Clinical Oncology 23(16_suppl): 6551-6551, 2016

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100(4): 1224-1232, 2002